Table des matières 2007-2008 - IRCM

The ethics of neuroenhancement, Département dephilosophie, University of Western Ontario, London,OntarioResearcher responsibility, ethics, and public expectationsregarding clinical and basic neuroscience, Centre deneurosciences, University of Alberta, Edmondon, AlbertaEthics in chronic disorders of consciousness: Identifyingkey public understanding challenges based on the Schiavosaga, Groupe de neuroéthique, University ofPennsylvania, Philadelphie, PennsylvanieThe brain at the intersection of ethics and the public,Institute for Research in Cognitive Science, University ofPennsylvania, Philadelphie, PennsylvanieTimothy L. REUDELHUBERProrenin: Good guy or bad guy? Lady Davis ResearchInstitute, Montréal, QuébecIs prorenin a threat to health? Wyeth Pharmaceuticals,Philadelphie, PennsylvanieMolecular anatomy of regulated protein secretion, Institutde recherche en santé d’Ottawa, Université d’Ottawa,Ottawa, OntarioFrançois ROBERTMapping chromatin structure and dynamics at the genomiclevel, Centre de recherche du CHU Sainte-Justine,Montréal, QuébecGenome-wide mapping of chromatin structure anddynamics in yeast and mammals, Institut de rechercheen immunologie et en cancérologie (IRIC), Universitéde Montréal, Montréal, QuébecMapping chromatin structure and dynamics at the genomicscale, Terrence Donnelly Centre for Cellular andBiomolecular Research (Donnelly CCBR), University ofToronto, Toronto, OntarioThe role of chromatin in the regulation of nuclearprocesses in yeast and mammals, Department ofBiochemistry, University of Alberta, Edmonton, AlbertaM. Ram SAIRAMChronology of ovarian tumorigenesis and identification ofnovel tumor associated genes (OTAG s ), LouisianaCancer Research Center Seminar Series, New Orleans,États-UnisPeter W. SCHILLERCell-penetrating, mitochondria-targeted antioxidants,Département de recherche, Hôpital universitaire,Université de Bâle, Bâle, SuisseFrom orally active opioid peptide analgesics tomitochondria-targeted antioxidants, Department ofBiochemistry and Cancer Biology, University of Toledo,Toledo, OhioFrom orally active opioid peptide analgesics tomitochondria-targeted antioxidants, Institut de rechercheen santé d'Ottawa, Ottawa, OntarioBi- or multifunctional drugs, Dept. of Chemistry, NationalUniversity of Singapore, SingaporeSS-Peptides: New developments, Stealth PeptidesInternational, Inc., New York, New YorkNabil G. SEIDAHThe proprotein convertase PCSK9 and its role in lipidmetabolism, Abbott laboratories, Abbott Park, IllinoisThe proprotein convertase: phyisological and pathologicalroles, Department of Anatomy and Cell Biology and Facultyof Dentistry, Division of Biomedical Sciences, UniversitéMcGill, Montréal, QuébecThe proprotein convertases: cellular biology andphysiology, Research Group in the Life SciencesInstitute (LSI), University of British Columbia, Vancouver,Colombie BritanniqueThe versatile proprotein convertases in health and disease,University of Pittsburgh, Drug Discovery Institute,Pittsburgh, PennsylvaniaThe role of the proprotein convertases in dyslipidemias,with emphasis on PCSK9, Canadian LipoproteinConference (CLC), Mont Sainte Anne, QuébecThe role of the proprotein convertases in the metabolicsyndrome and the development of diabetes, QatarUniversity, Doha, QatarThe proprotein convertases and their roles inneuroendocrine dysfunctions, Wyeth NeuroscienceDiscovery, Princeton, New JerseyThe physiological and pathological functions of theproprotein convertases: emphasis on PCSK9, RinatNeuroscience, Pfizer Global Research andDevelopment, San Francisco, CalifornieThe role PCSK9 in liver and gut, Bristol Myers Squibb,Princeton, New JerseyImplication of the proprotein convertases in cardiovascular63